Bristol Myers Squibb Partners With Hengrui Pharma on Early-Stage Programs
Bristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs. The agreement is the latest instance of a global pharmaceutical company seeking medicines from China. Separately, Viiv lost an HIV treatment patent case while other companies reported regulatory and commercialization developments.
manilatimes.netBristol Myers Squibb announced a partnership with Hengrui Pharma covering more than a dozen early-stage programs. The deal represents the latest and notably large example of a global pharmaceutical company looking to China for its next medicines, according to a report published Tuesday.
The company did not disclose further financial terms of the agreement in the initial announcement. The partnership aims to restock Bristol Myers Squibb's early-stage pipeline.
Pharma will market the newly approved breast cancer drug Veppanu under a commercialization agreement signed with Arvinas and Pfizer. Roche received European clearance for a new blood test designed to detect early Alzheimer’s disease. BridgeBio submitted an application to the FDA seeking approval of its drug encaleret to treat patients with autosomal dominant hypocalcemia type 1, also known as ADH1.
The rare genetic disease causes low calcium levels in the blood.
Additional News Viiv lost an HIV treatment case.
Hims reported sales that missed expectations as telehealth competition grows. A series investigating the alcohol epidemic in the U.S. launched on the same day. The stories examine factors ranging from the influence of the alcohol industry to gaps in treatment options for addiction.
Key Facts
Potential Impact
- 01
Rigel Pharma begins commercialization of newly approved breast cancer drug Veppanu.
- 02
Bristol Myers Squibb gains access to more than a dozen early-stage programs from Hengrui Pharma.
- 03
Roche can now offer its blood test for early Alzheimer’s detection across Europe.
- 04
BridgeBio advances encaleret toward potential approval for treating rare genetic disease ADH1.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…